Prognostic significance of inflammatory indices in hepatocellular carcinoma treated with transarterial chemoembolization: A systematic review and meta-analysis

Shuangshuang Li¹, Xudong Feng², Guodong Cao³, Qianhui Wang⁴, Ling Wang*¹

¹ Department of Microbiology and Center of Infectious Disease, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People’s Republic of China, ² State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang province, People’s Republic of China, ³ Department of Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People’s Republic of China, ⁴ Department of Infectious Diseases, Taiyuan No. 3 Hospital, Taiyuan, Shanxi Province, People’s Republic of China

* lingwang@bjmu.edu.cn

Abstract

Objectives
To investigate the association between inflammatory indices and clinical outcomes of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE) by performing meta-analysis.

Methods
A systematic literature search for relevant studies published up to August 2019 was performed by using PubMed, Web of Science, EMBASE, China National Knowledge Internet (CNKI) and Wanfang databases. Pooled hazard ratios (HR) or odds ratio (OR) and 95% confidence intervals (95% CI) were calculated.

Results
A total of 5280 patients from 22 studies were finally enrolled in the meta-analysis. The results demonstrated that elevated preoperative NLR, PLR, and CRP was associated with poor OS in HCC patients treated by TACE (HR = 1.81, P < 0.00001; HR = 1.56, P = 0.007; HR = 1.45, P < 0.00001, respectively). In addition, high NLR was significantly correlated with the presence of tumor vascular invasion (OR = 1.49, P = 0.002). Elevated PLR tended to be correlated with higher incidence of tumor size >3 cm (OR = 2.42, P = 0.005).

Conclusions
Elevated preoperative NLR, PLR, and CRP are associated with poor prognosis in HCC patients treated with TACE. These inflammatory indices may be convenient, accessible,
affordable and dependable biomarkers with prognostic potential for HCC patients treated by TACE.

**Introduction**

Hepatocellular carcinoma (HCC), a highly aggressive and prevalent tumor with increasing incidence rate over the last several decades, is the seventh most common malignant tumors worldwide and the fourth leading cause of cancer-related mortality[1]. Resection, liver transplantation may be curative for the early stage of tumor, which accounts for ≤ 30% of patients[2]. However, most of patients with hepatocellular carcinoma are initially diagnosed at an intermediate to advanced stage, where hepatic resection and liver transplantation are not feasible[3]. Transarterial chemoembolization (TACE) is considered to be the standard treatment for patients at intermediate stage according to the Barcelona Clinic Liver Cancer classification (BCLC) stage[4]. TACE can be used to treat well-compensated cirrhosis patients, which can reduce their burden of disease and potentially prolong their life. It is a non-surgical, minimally invasive and well-tolerated procedure with acceptable morbidity[5]. A few criteria have been proposed to predict the prognosis of patients and to help clinicians design optimal personalized treatment strategies, like Tumor Node Metastasis (TNM), functional liver reserve, Cancer of the Liver Italian Program (CLIP) staging score and Barcelona Clinic Liver Cancer (BCLC) score[6]. However, due to the tedious content of these standards, there are many inconveniences in practical applications. Although these criteria are mostly efficient in predict patients prognosis, they add a lot of burden to clinicians and patients, which explains why they are rarely used in routine clinical practice[6]. Therefore, it is essential to identify effective, common and easy-obtained prognostic biomarkers, especially simple serum biomarkers for prognosis of HCC undergoing TACE.

Homogeneous inflammation is vital for health; insufficient inflammation may lead to persistent infection of pathogens, while excessive inflammation may cause chronic or systemic inflammatory diseases[7]. Since the discovery of the close relationship between inflammation and malignancy in 1863, increasing evidence has suggested that the presence of a systemic inflammatory response is highly correlated with poor prognosis for malignancies[8–10]. Moreover, the presence of a systemic inflammatory response can be detected by C-reactive protein (CRP) and inflammation-related cells, including neutrophils, lymphocytes, and platelets. NLR values represent the absolute neutrophil count divided by the absolute lymphocyte count. PLR values represent the absolute platelet count divided by the absolute lymphocyte count. Thus, a variety of inflammatory indices such as CRP, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), modified Glasgow prognostic score (mGPS) and prognostic nutritional index (PNI) have been proposed and have been proven to have prognostic value in multiple cancers[11–17]. However, as a matter of contradictory results as well as the small sample size in solitary study, the current opinion of inflammatory indices as the prognostic markers in HCC patients treated with TACE is still inconclusive.

We therefore collected the eligible studies and conducted this meta-analysis to investigate the relationship between some novel inflammatory indices and the prognosis of HCC patients treated with TACE.

**Materials and methods**

**Literature search strategy**

The following databases were systematically searched until August 2019 without time restrictions: PubMed, Web of Science, EMBASE, China National Knowledge Internet (CNKI) and
Wanfang databases. The search strategy was based on combination of following terms: ("NLR" or "neutrophil to lymphocyte ratio" or "neutrophil-lymphocyte ratio" or "PLR" or "platelet to lymphocyte ratio" or "platelet-lymphocyte ratio" or "C-reactive protein" or "CRP" or "prognostic nutritional index" or "PNI") AND ("hepatocellular carcinoma" or "HCC" or "liver carcinoma" or "liver cancer") AND ("TACE" or "transarterial chemoembolization"). References cited in the retrieved articles were also scanned for relevant studies. Two assessors independently screened the title and abstract of each study. Once relevant studies became certain, the full texts were obtained for further evaluation.

Selection and exclusion criteria

Studies included in the meta-analysis had to meet the following criteria: (1) HCC was diagnosed by pathological methods; (2) inflammatory indices was measured by serum-based methods before TACE treatment; (3) hazard ratios (HR) and 95% confidence intervals (95% CI) for different inflammatory indices in overall survival (OS) were described in the study or could be calculated from the supplied data. The exclusion criteria were as follows: (1) letters, reviews, comments, conference abstract, full text not available; (2) articles without deficit cut-off value of indices; (3) overlapping or duplicate data; (4) TACE combined with sorafenib treatment.

Data extraction and quality assessment

Data were extracted separately by two reviewers, and disagreement was resolved by joint discussion. The following data of each study were recorded: name of first author, year of publication, research time, country, sample size, patients' age, gender, BCLC stage, Child-Pugh score, treatment methods, inflammation indices, cut-off value, time of follow-up, survival data, and clinicopathologic parameters. The quality of the included studies was assessed using the 9-star Newcastle-Ottawa Scale (NOS) by two independent reviewers. The NOS consists of three aspects: selection, comparability, and outcome assessment between the case group and the control group. Studies with the NOS scores ≥ 6 were regarded as high-quality studies. The consensus about the quality of studies was achieved as disagreement between the two reviewers was resolved through discussion.

Data analysis

HR and their associated standard errors (SE) were pooled to give the effective value for the quantitative aggregation of the survival results. When these statistical variables are not directly available in the original article, they were calculated from the available data using methods reported by Parmar et al.[18]. For the pooled analysis of the relationship between inflammation index (NLR, PLR) and clinical features, odds ratio (OR) and their 95% CI were pooled to give the effective value.

The Review Manager version 5.3 and STATA software (version 12.0) were used for data analysis. The heterogeneity between studies was assessed by the chi-squared and I-squared tests. If heterogeneity was significant (I^2 ≥ 50%), random-effect model was used to calculate the pooled HR and 95% CI. Otherwise, fixed-effect model was performed. All P values were two-tailed with a significant level at 0.05. Log (HR) and their associated standard errors (selog (HR)) were pooled to conduct the Begg's funnel plots. Begg's rank correlation was used to determine potential publication bias. P value less than 0.05 indicates statistically significant publication bias.
Results

Literature information

In total, 294 potentially relevant records were initially identified after searching PubMed, Web of Science, EMBASE, CNKI and Wanfang databases (Fig 1). After removal of duplicates, 168 studies were selected and screened for eligibility. Of these, 111 irrelevant records were excluded after screening the titles or abstracts. After carefully reading the full text of the remaining 57 studies, 35 papers that did not meet the inclusion criteria were further excluded. Subsequently, 22 studies were included in qualitative synthesis.

Characteristics of included studies

A total of 22 studies[2,5,19–38] published between 2011 and 2019 were identified and all these trials were retrospective cohort studies with 5280 patients enrolled in this meta-analysis. The basic characteristics of the included studies were summarized and presented in Table 1. Sixteen studies were conducted in China, the other six studies were conducted in Korea, Australia, Germany, USA, Japan, Italy, respectively. All the studies were HCC patients received TACE and OS data were reported or estimated. Sample sizes ranged from 49 to 921. Of the 22 studies, 16 of studies[2,5,19,21,23–25,27–34,37] were about the prognostic value of preoperative NLR for OS, 5 about PLR[23,24,26,32,33] and 6 about CRP[20,22,33,35,36,38]. The NLR cut-off values in these studies were determined by different methods and ranged from 1.77 to 5. The
| Author/ year | Country | Treatment | Sample size (n, male) | BCCL stage | Child-Pugh class | Sampling time | Mean/ median ages (years) | Follow-up time (months) | Inflammation index | Cut-off value | Outcome | NOS score |
|-------------|---------|-----------|----------------------|------------|-----------------|---------------|--------------------------|-----------------------|------------------|--------------|---------|----------|
| Chon 2019   | Korea   | cTACE     | 921(700)             | A/B/C      | A/B             | before TACE   | 68.2                     | 13–61.4               | NLR              | NLR = 5      | OS       | 7        |
| Fan 2015    | China   | cTACE     | 132(87)              | NA         | A/B             | before TACE   | 49           | 4–46                  | NLR/PLR             | NLR = 3.1     | PLR = 137 | OS       | 7        |
| He 2019     | China   | cTACE     | 216(200)             | B/C        | A/B             | before TACE   | 53           | 1–56                  | NLR/PLR/CRP         | NLR = 1.77    | PLR = 94.62| CRP = 0.8mg/dl | OS       | 8        |
| Huang 2011  | China   | cTACE     | 145(134)             | NA         | A               | before TACE   | 49           | 1–41                  | NLR                 | NLR = 3.3     | OS       | 8        |
| Hucke 2014  | Australia | cTACE/ DEB-TACE | 131(115)     | A/B         | A/B             | before TACE   | 66           | NA                   | CRP                 | CRP = 1mg/dl | OS       | 7        |
| Le 2019     | China   | cTACE     | 303(274)             | C          | A/B             | before TACE   | 53           | NA                   | CRP                 | CRP = 0.5mg/dl | OS       | 7        |
| Li 2013     | China   | cTACE     | 154(134)             | NA         | A               | before TACE   | 50           | 1–41                  | NLR                 | NLR = 2.5     | OS       | 7        |
| Li 2016     | China   | cTACE     | 117(86)              | B/C        | NA              | before TACE   | 51.74        | 3–36                  | CRP                 | CRP = 1mg/dl | OS       | 7        |
| Liu 2017    | China   | cTACE     | 760(643)             | B/C        | A/B             | before TACE   | 56.5         | 1–69                  | NLR                 | NLR = 2.2     | OS       | 8        |
| Mahringer- Kunz 2017 | Germany | cTACE/ DEB-TACE | 228(192)     | A/B         | A/B             | before TACE   | 66.8         | NA                   | CRP                 | CRP = 1mg/dl | OS       | 7        |
| McNally2013 | USA      | cTACE/ DEB-TACE | 104(77)       | NA         | A/B/C           | before TACE   | 56           | 1–56                  | NLR                 | NLR = 5      | OS       | 7        |
| Ogasawara 2015 | JAPAN | cTACE     | 187(139)             | B          | A/B             | before TACE   | 70           | NA                   | CRP                 | CRP = 1mg/dl | OS       | 7        |
| Rebonato 2017 | Italy   | cTACE/ DEB-TACE | 49(39)         | B/C        | A/B             | before TACE   | 75           | 1–53                  | NLR                 | NLR = 2.03    | OS/PFS | 8        |
| Sun 2018    | China   | cTACE     | 95(84)               | B          | A               | before TACE   | 54.1         | 8–50                  | NLR/PLR             | NLR = 2.51    | OS       | 7        |
| Tian 2016   | China   | cTACE     | 122(107)             | NA         | A/B             | before TACE   | 56           | NA                   | NLR/PLR             | NLR = 2.61    | PLR = 96.13  | OS       | 7        |
| Xu 2014     | China   | cTACE     | 178(149)             | B          | A               | before TACE   | 54.3         | 1–99                  | NLR                 | NLR = 1.85    | OS       | 8        |
| Xue 2015    | China   | cTACE     | 291(258)             | B/C        | A/B             | before TACE   | 53           | 1–61                  | PLR                 | PLR = 150     | OS       | 8        |
| Yang 2015   | China   | cTACE     | 546(453)             | NA         | A/B             | before TACE   | 52           | 4–78                  | NLR                 | NLR = 3      | OS       | 8        |
| Zhang 2014  | China   | cTACE     | 138(99)              | NA         | A/B             | before TACE   | 56.8         | NA                   | NLR                 | NLR = 5      | OS       | 7        |
| Zheng 2013  | China   | cTACE     | 77(67)               | B/C        | A/B             | before TACE   | 56.7         | 2–48                  | NLR                 | NLR = 4      | OS       | 8        |
| Zhou 2016   | China   | cTACE     | 279(251)             | NA         | A/B             | before TACE   | 50           | 1–52                  | NLR                 | NLR = 2.6     | OS       | 8        |
| Zou 2017    | China   | cTACE     | 107(94)              | B/C        | NA              | before TACE   | 50           | 1–100                 | NLR                 | NLR = 2      | OS/DFS | 5        |

TACE, transarterial chemoembolization; NLR, neutrophil-lymphocyte ratio; PLR, platelet to lymphocyte ratio; cTACE, conventional TACE; DEB-TACE, drug-eluting beads TACE
CRP, C-reactive protein; NA, not available; OS, overall survival; PFS, progression-free survival; DFS, disease-free survival; NOS score, Newcastle–Ottawa Quality Assessment Scale.

https://doi.org/10.1371/journal.pone.0230879.t001
cut-off values used for PLR ranged from 94.62 to 150. The cut-off values used for CRP ranged from 0.5 to 1 mg/dl.

**Quality assessment**

As Table 1 shows, there are nine studies with a NOS score of 8, twelve studies with a NOS score of 7, one study with a NOS score of 5 according to the NOS criteria. The mean score of the included studies was 7 (ranging from 5 to 8). Approximately 95% studies possessed good quality according to our definition for high-quality studies.

**The prognostic value of preoperative NLR for OS**

There were 16 studies investigating the association between preoperative NLR and OS of HCC patients who underwent TACE. Elevated preoperative NLR was significantly associated with poor OS with the pooled HR being 1.81 (95% CI: 1.66–1.97, \( P < 0.00001 \)), demonstrating that elevated preoperative NLR was an indicator of poor survival rate in HCC patients initially treated with TACE (Fig 2A). Although heterogeneity was found among these studies (\( P = 0.02, \ I^2 = 47\% \)), the analysis was estimated using a fixed-effect model according to our model selection criteria. Subgroup analysis was also conducted to further investigate the prognostic effects of NLR on OS. In the subgroup, according to the cut-off value of NLR, statistically significance was found respectively in NLR = 5.0 (HR = 1.74, 95% CI: 1.44–2.11), 2.5 ≤ NLR < 5 (HR = 1.69, 95% CI: 1.50–1.91), and NLR < 2.5 (HR = 2.06, 95% CI: 1.77–2.40). Surprisingly, in the NLR = 5.0 subgroup, the result indicated high statistical heterogeneity with an \( I^2 \) value of 77\% (\( P = 0.01 \)), whereas no significant heterogeneity between studies was found in subgroup 2.5 ≤ NLR < 5 and subgroup NLR < 2.5, suggesting that NLR cut-off value for each study may be the source of heterogeneity of the pooled analysis. The funnel plot is used to assess the publication bias of the included literature, and we can roughly assess publication bias by observing whether its shape has any significant asymmetry. The funnel plot showed no clear evidence of publication bias, except that one trial was out of the symmetric region (Fig 2B). Begg’s test (\( P = 0.064 \)) also provided a statistical evidence of the absence of significant publication bias.

**The prognostic value of preoperative PLR for OS**

Five studies were included to evaluate the association between preoperative PLR and OS of patients with HCC. Since heterogeneity was found among these studies, (\( I^2 = 59\% , P = 0.04 \)), random-effect model was adopted to calculate the combined HR. Pooled data revealed that elevated PLR was significantly associated with poor OS with a pooled HR of 1.56 (95% CI: 1.13–2.16, \( P = 0.007; \) Fig 3), suggesting that elevated PLR was also an indicator of poor survival rate in HCC patients treated with TACE. Every single study was omitted every time to estimate the influence of individual data sets on the pooled HR in Table 2. When removing the study of Sun 2018[48], we observed the heterogeneity between studies was significantly decreased (\( I^2 = 19\% , P = 0.30 \)), indicating that this study could affect the significance of between-study homogeneity. The sensitive results for the association between preoperative PLR and overall survival were presented in S1 Fig.

**The prognostic value of preoperative CRP for OS**

Six studies provided available data for evaluating the prognostic value between CRP and OS of HCC patients undergoing TACE. As no significant heterogeneity between studies was observed (\( I^2 = 12\% , P = 0.34 \)), fixed-effect model was used to estimate the combined HR of OS.
A

| Study or Subgroup | log[Hazard Ratio] | SE  | Weight | Hazard Ratio [IV, Fixed, 95% CI] | Hazard Ratio [IV, Fixed, 95% CI] |
|-------------------|-------------------|-----|--------|----------------------------------|----------------------------------|
| NLR<5             |                   |     |        |                                  |                                  |
| Chon 2019         | 0.32              | 0.13| 19.9%  | 1.38 [1.07, 1.78]                |                                  |
| McNally 2013      | 1.07              | 0.25| 3.0%   | 2.92 [1.79, 4.76]                |                                  |
| Zhang 2014        | 0.76              | 0.19| 5.1%   | 2.14 [1.47, 3.10]                |                                  |
| Subtotal (95% CI) |                   |     | 19.9%  | 1.74 [1.44, 2.11]                |                                  |
| Heterogeneity: Chi² = 8.68, df = 2 (P = 0.01); I² = 77% | | | | |
| Test for overall effect: Z = 5.83 (P < 0.00001) | | | | |

2.5≤ NLR<5

| Study or Subgroup | log[Hazard Ratio] | SE  | Weight | Hazard Ratio [IV, Fixed, 95% CI] | Hazard Ratio [IV, Fixed, 95% CI] |
|-------------------|-------------------|-----|--------|----------------------------------|----------------------------------|
| Fan 2015          | 0.61              | 0.24| 3.2%   | 2.25 [1.40, 3.60]                |                                  |
| Huang 2011        | 0.52              | 0.15| 8.2%   | 1.68 [1.25, 2.26]                |                                  |
| Li 2013           | 0.54              | 0.11| 15.3%  | 1.72 [1.38, 2.13]                |                                  |
| Sun 2018          | 0.92              | 0.27| 2.5%   | 2.51 [1.48, 4.26]                |                                  |
| Tian 2016         | 0.11              | 0.27| 2.5%   | 1.12 [0.66, 1.89]                |                                  |
| Yang 2015         | 0.61              | 0.22| 3.8%   | 1.84 [1.20, 2.83]                |                                  |
| Zheng 2013        | 0.67              | 0.33| 1.7%   | 2.39 [1.25, 4.56]                |                                  |
| Zhou 2016         | 0.38              | 0.12| 12.8%  | 1.46 [1.18, 1.86]                |                                  |
| Subtotal (95% CI) |                   |     | 50.1%  | 1.89 [1.50, 1.91]                |                                  |
| Heterogeneity: Chi² = 8.63, df = 7 (P = 0.28); I² = 19% | | | | |
| Test for overall effect: Z = 8.68 (P < 0.00001) | | | | |

NLR<2.5

| Study or Subgroup | log[Hazard Ratio] | SE  | Weight | Hazard Ratio [IV, Fixed, 95% CI] | Hazard Ratio [IV, Fixed, 95% CI] |
|-------------------|-------------------|-----|--------|----------------------------------|----------------------------------|
| He 2019           | 0.91              | 0.25| 3.0%   | 2.48 [1.52, 4.06]                |                                  |
| Liu 2017          | 0.76              | 0.1  | 18.5%  | 2.14 [1.76, 2.60]                |                                  |
| Rebonato 2017     | 2.44              | 0.61| 0.3%   | 11.47 [2.35, 55.12]              |                                  |
| Xu 2014           | 0.52              | 0.26| 2.7%   | 1.68 [1.01, 2.90]                |                                  |
| Zou 2017          | 0.54              | 0.17| 6.4%   | 1.72 [1.23, 2.39]                |                                  |
| Subtotal (95% CI) |                   |     | 38.9%  | 2.89 [1.77, 4.90]                |                                  |
| Heterogeneity: Chi² = 6.96, df = 4 (P = 0.14); I² = 43% | | | | |
| Test for overall effect: Z = 9.34 (P < 0.00001) | | | | |
| Total (95% CI)    |                   |     | 100.0% | 1.81 [1.66, 1.97]                |                                  |
| Heterogeneity: Chi² = 28.41, df = 15 (P = 0.02); I² = 47% | | | | |
| Test for overall effect: Z = 13.79 (P < 0.00001) | | | | |
| Test for subdomain differences: Chi² = 4.14, df = 2 (P = 0.13); I² = 51.7% | | | | |

B

Begg's funnel plot with pseudo 95% confidence limits

log(OR) vs. s.e. of log(OR)
The pooled HR revealed an obvious association between CRP and HCC, with the pooled HR being 1.45 (95% CI: 1.24–1.70, \(P < 0.00001\); Fig 4A). Moreover, the Begg’s funnel plot was symmetric and no publication bias was detected (\(P = 0.452\)) (Fig 4B). Therefore, the results indicated that patients with high pretreatment CRP had poor OS.

Preoperative NLR and clinical features

The associations between NLR and clinical parameters were summarized in Table 3. Six studies provided data about the correlation between elevated NLR and vascular invasion. Pooled results showed that the incidence of elevated preoperative NLR had a significant association with the presence of tumor vascular invasion (OR = 1.49, 95% CI 1.15–1.92, \(P = 0.002\)). However, there is no significant correlation between NLR and the other nine clinical features. As no significant heterogeneity between studies was found, fixed-effect models were used except tumor size and serum AFP level.

Preoperative PLR and clinical features

Pooled data of 244 HCC patients showed that high PLR tended to be correlated with higher incidence of tumor size \(>3\) cm (OR = 2.42, 95% CI: 1.31–4.48, \(P = 0.005\)). As for the other five clinical features: gender, serum AFP level, Child-Pugh class, vascular invasion, presence of HBV, combined data did not show statistical significance. Since no significant heterogeneity between studies was found, fixed-effect models were used except serum AFP level (Table 4).

Discussion

At present, inflammation, as a protective response, plays a critical role in the initiation and progression of malignancies, which has aroused widespread interest despite the unclear mechanism. NLR, PLR, and C-reactive protein (CRP) are often used as hematological markers of systemic inflammation to reflect the balance between the host inflammatory response and immune response\[39\]. The association between inflammation markers (NLR, PLR, CRP) and cancer has already been observed in various types of gastrointestinal malignancies, including esophageal cancer, gastric cancer, colorectal cancer, and pancreatic cancer\[38,40–44\].

---

Fig 2. Correlation between NLR and overall survival of HCC treated by TACE. (A) Forest plot of comparison of the included trials. (B) Funnel plot of comparison of the included trials.

https://doi.org/10.1371/journal.pone.0230879.g002

The pooled HR revealed an obvious association between CRP and HCC, with the pooled HR being 1.45 (95% CI: 1.24–1.70, \(P < 0.00001\); Fig 4A). Moreover, the Begg’s funnel plot was symmetric and no publication bias was detected (\(P = 0.452\)) (Fig 4B). Therefore, the results indicated that patients with high pretreatment CRP had poor OS.

Preoperative NLR and clinical features

The associations between NLR and clinical parameters were summarized in Table 3. Six studies provided data about the correlation between elevated NLR and vascular invasion. Pooled results showed that the incidence of elevated preoperative NLR had a significant association with the presence of tumor vascular invasion (OR = 1.49, 95% CI 1.15–1.92, \(P = 0.002\)). However, there is no significant correlation between NLR and the other nine clinical features. As no significant heterogeneity between studies was found, fixed-effect models were used except tumor size and serum AFP level.

Preoperative PLR and clinical features

Pooled data of 244 HCC patients showed that high PLR tended to be correlated with higher incidence of tumor size \(>3\) cm (OR = 2.42, 95% CI: 1.31–4.48, \(P = 0.005\)). As for the other five clinical features: gender, serum AFP level, Child-Pugh class, vascular invasion, presence of HBV, combined data did not show statistical significance. Since no significant heterogeneity between studies was found, fixed-effect models were used except serum AFP level (Table 4).

Discussion

At present, inflammation, as a protective response, plays a critical role in the initiation and progression of malignancies, which has aroused widespread interest despite the unclear mechanism. NLR, PLR, and C-reactive protein (CRP) are often used as hematological markers of systemic inflammation to reflect the balance between the host inflammatory response and immune response\[39\]. The association between inflammation markers (NLR, PLR, CRP) and cancer has already been observed in various types of gastrointestinal malignancies, including esophageal cancer, gastric cancer, colorectal cancer, and pancreatic cancer\[38,40–44\].

---

Fig 3. Forest plot of hazard ratio (HR) for the association of PLR with OS in HCC patients treated with TACE.

https://doi.org/10.1371/journal.pone.0230879.g003
Previously, a meta-analysis demonstrated that elevated preoperative NLR is associated with poor prognosis in HCC patients treated with liver transplantation, and NLR could be used as a marker to predict the survival rate and tumor recurrence rate in HCC patients after liver transplantation [45]. Another meta-analysis indicated that preoperative NLR had significant association with the prognosis of HCC patients underwent curative hepatectomy and may be an effectively prognostic indicator [46]. Moreover, Lin et al. evaluated the prognostic significance of PLR in HCC patients with a total of 2449 patients from 9 studies. The results demonstrated that PLR may be a significant biomarker in the prognosis of HCC in different BCLC stages [7].

CRP is one of the most commonly used indicators for assessing the magnitude of systemic inflammatory response because of its high sensitivity in hospital labor, good specificity, and high reproducibility. Since Hashimoto et al. first demonstrated that the preoperative serum CRP level is an independent and significant factor predictive of a poor prognosis in patients undergoing surgical resection, several investigators have identified an elevated serum CRP level to be an indicator of poor outcomes in HCC patients undergoing transplantation, TACE and radiofrequency ablation [47–51].

This meta-analysis was performed to assess the prognostic value of inflammation markers such as NLR, PLR, and CRP in HCC patients treated with TACE. In the present study, we utilized the available data from 16 included studies with a total of 4023 patients to obtain the pooled results to evaluate the predicted role of NLR in HCC. The pooled outcomes statistically supported the conclusions that elevated NLR predicted poor OS (HR = 1.81, 95% CI: 1.66–1.97, P < 0.00001) in HCC patients treated with TACE. In the subgroup analysis, statistically significance was found respectively in subgroup NLR = 5.0 (HR = 1.74, 95% CI: 1.44–2.11), 2.5 ≤ NLR < 5 (HR = 1.69, 95% CI: 1.50–1.91), and NLR < 2.5 (HR = 2.06, 95% CI: 1.77–2.40). The clinical features of HCC, such as tumor multifocality and vascular invasion, are related to the prognosis and survival of HCC [52]. In this case, we performed a pooled analysis to assess the association between elevated NLR and clinical features in HCC. The result indicated that the incidence of high preoperative NLR had significant association with the presence of tumor vascular invasion (OR = 1.49, 95% CI: 1.15–1.92, P = 0.002). In addition, five studies reported evidence about the correlation between elevated PLR and prognosis of HCC patients treated with TACE. Four studies suggested statistical significance, while one studies reported no correlation. Pooled data from all the five studies supported a correlation (HR = 1.56, 95% CI: 1.13–2.16, P = 0.007). Moreover, when we further analyzed the associations between pretreatment PLR and clinicopathologic parameters, we discovered that elevated PLR was linked with tumor size > 3 cm, which was consisted with the results of study Song [53]. Similarly, the pooled outcomes from six included primary studies demonstrated that elevated CRP predicted poor OS in HCC. These results above suggested that elevated preoperative NLR, PLR, and CRP can be used as indicators of poor survival rate in HCC patients treated with TACE.
It is noted that several limitations of this current meta-analysis should be carefully consid-
ered. Firstly, considering all the enrolled studies are retrospective, there may be some bias in
this meta-analysis, such as information bias, misclassification bias, and selection bias. Sec-
ondly, the sample size is so small that only 5 trials were enrolled in the analysis of the correla-
tion between PLR and OS and only 6 trials reported the evidence of the correlation between
PLR and OS. Besides, the greatest limitation was the discordance of the cut-off values of the
inflammation index used in the included studies. As mentioned earlier, the cut-off value of
NLR varies from 1.77 to 5, the cut-off value for PLR ranges from 94.62 to 150, and the cut-off value for CRP ranges from 0.5 to 1 mg/dl. In a way, this difference may account for the heterogeneity between studies. Considering these limitations above, the pooled HR or OR calculated in this study may be just estimation, and more studies that are well-designed, prospective and large-scale are needed to substantiate our results.

In conclusion, we could cautiously come to the conclusion that elevated preoperative NLR, PLR, and CRP are associated with poor prognosis in HCC patients treated with TACE, and they should be used as markers to predict the survival rate and assess the outcomes in HCC patients treated with TACE.

OR, odds ratio; CI, confidence intervals; HBV, hepatitis B virus; FEM, fixed-effects model; REM, random-effects model; P_{h}: p value of Q test for heterogeneity.

Table 3. The association between incidence of elevated preoperative NLR and clinical features.

| Clinical features                  | Number of studies | Number of patients | OR (95%CI)     | P     | Effects model | Heterogeneity |
|-----------------------------------|-------------------|--------------------|----------------|-------|---------------|---------------|
| Gender (male vs. female)          | 9                 | 1655               | 1.00 (0.76, 1.32) | 0.99  | FEM           | 36 0.13       |
| Tumor size (> 5cm vs. < 5cm)      | 5                 | 971                | 1.08 (0.60, 1.93) | 0.80  | REM           | 55 0.06       |
| BCLC stage (C vs. B)              | 2                 | 126                | 0.65 (0.28, 1.50) | 0.32  | FEM           | 0 0.52        |
| Vascular invasion (yes vs. no)    | 6                 | 1333               | 1.49 (1.15, 1.92) | 0.002 | FEM           | 38 0.15       |
| AFP (>400ng/ml vs. <400ng/ml)     | 6                 | 882                | 1.15 (0.65, 2.05) | 0.62  | REM           | 73 0.002      |
| Child-Pugh class (B vs. A)        | 7                 | 1356               | 0.96 (0.74, 1.26) | 0.78  | FEM           | 0 0.73        |
| Extrahepatic spread (yes vs. no)  | 3                 | 376                | 0.91 (0.55, 1.52) | 0.73  | FEM           | 0 0.92        |
| HBV (pos. vs. neg.)               | 5                 | 627                | 0.99 (0.64, 1.52) | 0.96  | FEM           | 0 0.43        |
| Tumor number (≥ 2 vs. <2)         | 2                 | 299                | 1.38 (0.87, 2.19) | 0.18  | FEM           | 0 0.88        |
| Tumor number (≥ 3 vs. <3)         | 2                 | 181                | 1.17 (0.62, 2.20) | 0.63  | FEM           | 33 0.22       |

OR, odds ratio; CI, confidence intervals; HBV, hepatitis B virus; FEM, fixed-effects model; REM, random-effects model; P_{h}: p value of Q test for heterogeneity.

Table 4. The association between incidence of elevated preoperative PLR and clinical features.

| Clinical features                  | Number of studies | Number of patients | OR (95%CI)     | P     | Effects model | Heterogeneity |
|-----------------------------------|-------------------|--------------------|----------------|-------|---------------|---------------|
| Gender (male vs. female)          | 4                 | 640                | 0.80 (0.50, 1.26) | 0.33  | FEM           | 0 4           |
| Tumor size (> 5cm vs. < 5cm)      | 2                 | 254                | 2.42 (1.31, 4.48) | 0.005 | FEM           | 0 2           |
| AFP (>400ng/ml vs. < 400ng/ml)    | 4                 | 640                | 1.10 (0.55, 2.19) | 0.78  | REM           | 71 4           |
| Child-Pugh class (B vs. A)        | 3                 | 349                | 1.21 (0.64, 2.29) | 0.55  | FEM           | 12 3           |
| Vascular invasion (yes vs. no)    | 2                 | 423                | 0.97 (0.63, 1.48) | 0.87  | FEM           | 12 0.29       |
| HBV (pos. vs. neg.)               | 2                 | 227                | 0.76 (0.34, 1.69) | 0.51  | FEM           | 0 0.86        |

OR, odds ratio; CI, confidence intervals; HBV, hepatitis B virus; FEM, fixed-effects model; REM, random-effects model; P_{h}: p value of Q test for heterogeneity.

Supporting information

S1 Fig. Forest plot of sensitive results for the association between preoperative PLR and overall survival, which are generalized in Table 2. (TIF)

S1 File. The PRISMA flow diagram of this meta-analysis. (DOC)

S2 File. The PRISMA checklist of this meta-analysis. (DOC)
Author Contributions

Data curation: Xudong Feng.
Formal analysis: Shuangshuang Li.
Funding acquisition: Ling Wang.
Investigation: Shuangshuang Li.
Methodology: Guodong Cao.
Project administration: Ling Wang.
Software: Guodong Cao.
Supervision: Qianhui Wang, Ling Wang.
Validation: Xudong Feng, Guodong Cao.
Writing – original draft: Shuangshuang Li.
Writing – review & editing: Xudong Feng.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394–424. https://doi.org/10.3322/caac.21492 PMID: 30207593
2. Zhou D, Liang J, Xu L, He F, Zhou Z, Zhang Y, et al. Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization. Oncol Lett. 2016; 11: 2987–2994. https://doi.org/10.3892/ol.2016.4359 PMID: 27123051
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet (London, England). 2003; 362: 1907–17. https://doi.org/10.1016/S0140-6736(03)14964-1
4. Saraswat VA, Pandey G, Shetty S. Treatment algorithms for managing hepatocellular carcinoma. J Clin Exp Hepatol. 2014; 4: S80–9. https://doi.org/10.1016/j.jceh.2014.05.004 PMID: 25755616
5. Rebonato A, Graziosi L, Maiettini D, Marino E, De Angelis V, Brunese L, et al. Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Gastroenterol Res Pract. 2017; 2017: 4164130. https://doi.org/10.1155/2017/4164130 PMID: 28894464
6. Ma W, Zhang P, Qi J, Gu L, Zang M, Yao H, et al. Prognostic value of platelet to lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. Sci Rep. 2016; 6: 35378. https://doi.org/10.1038/srep35378 PMID: 27739490
7. Lin W, Zhong M, Zhang Y, Wang H, Zhao H, Cheng B, et al. Prognostic Role of Platelet-to-Lymphocyte Ratio in Hepatocellular Carcinoma with Different BCLC Stages: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2018; 2018: 5670949. https://doi.org/10.1155/2018/5670949 PMID: 30158964
8. Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Lawrence N, et al. Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. Eur Urol. 2016; 70: 358–64. https://doi.org/10.1016/j.euro.2016.02.033 PMID: 26924770
9. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013; 13: 759–71. https://doi.org/10.1038/nrc3611 PMID: 24154716
10. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet (London, England). 2001; 357: 539–45. https://doi.org/10.1016/S0140-6736(00)04046-0
11. Cescon M, Bertuzzo VR, Ercolani G, Ravaiol M, Odaldi F, Pinna AD. Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol. 2013; 19: 9174–82. https://doi.org/10.3748/wjg.v19.i48.9174 PMID: 24409045
12. Shen J, He L, Li C, Wen T, Chen W, Lu C, et al. Prognostic nomograms for patients with resectable hepatocellular carcinoma incorporating systemic inflammation and tumor characteristics. Oncotarget. 2016; 7: 80783–80793. https://doi.org/10.18632/oncotarget.13038 PMID: 27811374

13. Fu Y-P, Ni X-C, Yi Y, Cai X-Y, He H-W, Wang J-X, et al. A Novel and Validated Inflammation-Based Score (IBS) Predicts Survival in Patients With Hepatocellular Carcinoma Following Curative Surgical Resection: A STROBE-Compliant Article. Medicine (Baltimore). 2016; 95: e2784. https://doi.org/10.1097/MD.0000000000002784 PMID: 26886627

14. Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, et al. Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. Exp Ther Med. 2011; 2: 879–885. https://doi.org/10.3892/etm.2011.308 PMID: 22977592

15. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005; 103: 1856–64. https://doi.org/10.1002/cncr.20976 PMID: 15779015

16. Gomez D, Morris-Stiff G, Toogood GJ, Lodge JPA, Prasad KR. Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol. 2008; 97: 513–8. https://doi.org/10.1002/jso.21001 PMID: 18335453

17. Szkandra J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Samonigg H, et al. Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. Br J Cancer. 2013; 109: 2265–22. https://doi.org/10.1038/bjc.2013.595 PMID: 24094772

18. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998; 17: 2815–34. https://doi.org/10.1002/(sici)1097-0258(19981230)17:24<2815::aid-stm110>3.0.co;2-8 PMID: 9921604

19. Liu C, Jia BS, Zou BW, Du H, Yan LN, Yang JY, et al. Neutrophil-to-lymphocyte and aspartate-to-alanine aminotransferase ratios predict hepatocellular carcinoma prognosis after transarterial embolization. Med (United States). 2017;96. https://doi.org/10.1097/MD.00000000000028512 PMID: 29137051

20. Mähringer-Kunz A, Kloekcner R, Pitton MB, Düber C, Schmidtmann I, Galle PR, et al. Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2017; 40: 1017–1025. https://doi.org/10.1007/s00270-017-1606-4 PMID: 28197830

21. McNaill ME, Martinez A, Khabiri H, Guy G, Michaels AJ, Hanje J, et al. Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Surg Oncol. 2013; 20: 923–8. https://doi.org/10.1245/s10434-012-2639-1 PMID: 23978330

22. Ogawasawa S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, et al. A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization. PLoS One. 2015; 10: e0125244. https://doi.org/10.1371/journal.pone.0125244 PMID: 26290252

23. Sun W, Zhang A, Sui J, Sun D, Wang L, Li W. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prediction of prognosis of patients with hepatocellular carcinoma after TACE. Chinese J Interv Imaging Ther. 2018; 15: 722–726.

24. Tian X-C, Liu X-L, Zeng F-R, Chen Z, Wu D-H. Platelet-to-lymphocyte ratio acts as an independent risk factor for patients with hepatitis B virus-related hepatocellular carcinoma who received transarterial chemoembolization. Eur Rev Med Pharmacol Sci. 2016; 20: 2302–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/27338055 PMID: 27338055

25. Xu X, Chen W, Zhang L, Miao R, Zhou Y, Wan Y, et al. Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transarterial chemoembolization. Chin Med J (Engl). 2014; 127: 4204–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/25533382

26. Xue T-C, Jia Q-A, Ge N-L, Zhang B-H, Wang Y-H, Ren Z-G, et al. The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization. Tumour Biol. 2015; 36: 6045–51. https://doi.org/10.1007/s13277-015-2381-x PMID: 25731733

27. Yang X, Zhou S, Wen H, Li W, Li Z, Wu G, et al. Preoperative neutrophil-lymphocyte ratio as a prognostic predictor for transarterial chemoembolization for HBV-associated hepatocellular carcinoma. Chinese J Radiol. 2015; 49: 769–773.

28. Zhang J, Gong F, Li L, Zhao M, Song J. Diabetes mellitus and the neutrophil to lymphocyte ratio predict overall survival in non-viral hepatocellular carcinoma treated with transarterial chemoembolization. Oncol Lett. 2014; 7: 1704–1710. https://doi.org/10.3892/ol.2014.1896 PMID: 24765205

29. Chon YE, Park H, Hyun HK, Ha Y, Kim MN, Kim BK, et al. Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma.
30. Zheng YB, Zhao W, Liu B, Li Y, Hu BS, Lu LG. Prognostic significance of blood neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma undergoing TACE. Chinese J Interv Imaging Ther. 2013; 10: 523–526.

31. Zou W, Chen L, Huang X, Wang L, Jiang T, Song J, et al. The prognostic significance of aspartate aminotransferase to neutrophils ratio in HCC patients treated with TACE. J Interv Radiol. 2017; 26: 705–711.

32. Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS One. 2015; 10: e0119312. https://doi.org/10.1371/journal.pone.0119312 PMID: 2574214

33. He C, Zhang Y, Cai Z, Lin X. The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy. Cancer Manag Res. 2019; 11: 1391–1400. https://doi.org/10.2147/CMAR.S190545 PMID: 30863150

34. Huang Z-L, Luo J, Chen M-S, Li J-Q, Shi M. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol. 2011; 22: 702–9. https://doi.org/10.1016/j.jvir.2010.12.041 PMID: 21514523

35. Hucke F, Pinter M, Graziaedi I, Bota S, Vogel W, Müller C, et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol. 2014; 61: 1287–96. https://doi.org/10.1016/j.jhep.2014.07.002 PMID: 25016222

36. Le Y, Shen J-X, Zhang Y-F, He M-K, Kan A, Chen H-L, et al. Transarterial Chemoembolization related to Good Survival for Selected Patients with advanced Hepatocellular Carcinoma. J Cancer. 2019; 10: 665–671. https://doi.org/10.7150/jca.28528 PMID: 30719164

37. Li JP, Hu SL, Chen H, Bu WZ, Song JL. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. Chinese J Cancer Prev Treat. 2013; 20: 522–525.

38. Li Y, Jia H, Yu W, Xu Y, Li X, Li Q, et al. Nomograms for predicting prognostic value of inflammatory biomarkers in colorectal cancer patients after radical resection. Int J Cancer. 2016; 139: 220–31. https://doi.org/10.1002/ijc.30071 PMID: 26933932

39. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009; 12: 223–6. https://doi.org/10.1097/MCO.0b013e32832a7902 PMID: 19318937

40. Alfaifi M, Eom YW, Newsome PN, Baik SK. Mesenchymal stromal cell therapy for liver diseases. J Hepatol. 2018; 68: 1272–1285. https://doi.org/10.1016/j.jhep.2018.01.030 PMID: 29425678

41. Gu X, Gao X-S, Cui M, Xie M, Peng C, Bai Y, et al. Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer. Oncotarget. 2016; 7: 49878–49887. https://doi.org/10.18632/oncotarget.10490 PMID: 2479665

42. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2007; 73: 215–20. https://doi.org/10.1159/000127412 PMID: 18424885

43. Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol. 2011; 104: 504–10. https://doi.org/10.1002/jso.21986 PMID: 21618251

44. Kwon H-C, Kim SH, Oh SY, Lee S, Lee JH, Choi H-J, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers. 2012; 17: 216–22. https://doi.org/10.3109/1354750X.2012.656705 PMID: 22424597

45. Sun X, Shi X, Chen Y, Wang C, Ma Q, Lv G. Elevated Preoperative Neutrophil-Lymphocyte Ratio Is Associated with Poor Prognosis in Hepatocellular Carcinoma Patients Treated with Liver Transplantation: A Meta-Analysis. Gastroenterol Res Pract. 2016; 2016: 4743808. https://doi.org/10.1155/2016/4743808 PMID: 26683858

46. Wang Y, Peng C, Cheng Z, Wang X, Wu L, Li J, et al. The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: A systematic review and meta-analysis. Int J Surg. 2018; 55: 73–80. https://doi.org/10.1016/j.ijsu.2018.05.022 PMID: 29787804

47. Meischl T, Rasoul-Rockenschaub S, Györi G, Sieghart W, Reiberger T, Trauner M, et al. C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. Avila MA, editor. PLoS One. 2018; 14: e0216677. https://doi.org/10.1371/journal.pone.0216677 PMID: 31141535
48. An HJ, Jang JW, Bae SH, Choi JY, Yoon SK, Lee MA, et al. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2012; 18: 1406–14. https://doi.org/10.1002/lt.23512 PMID: 22821639

49. Shen S, Gong J, Yang Y, Qin S, Huang L, She S, et al. Molecular mechanism of C-reaction protein in promoting migration and invasion of hepatocellular carcinoma cells in vitro. Int J Oncol. 2017; 50: 1289–1298. https://doi.org/10.3892/ijo.2017.3911 PMID: 28350119

50. Kinoshita A, Onoda H, Imai N, Nishino H, Tajiri H. C-Reactive Protein as a Prognostic Marker in Patients with Hepatocellular Carcinoma. Hepatogastroenterology. 2015; 62: 966–70. https://doi.org/10.1016/j.ejso.2008.01.016 PMID: 26902038

51. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005; 103: 1856–64. https://doi.org/10.1002/cncr.20976 PMID: 15779015

52. Bruix J, Sherman M, Practice Guidelines Committee AA for the S of LD. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208–36. https://doi.org/10.1002/hep.20933 PMID: 16250051

53. Song W, Wang K, Zhong F-P, Fan Y-W, Peng L, Zou S-B. Clinicopathological and prognostic significance of platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma. Oncotarget. 2016; 7: 81830–81838. https://doi.org/10.18632/oncotarget.13244 PMID: 27833084